Fatty Liver, A Big, Fatty Opportunity for Big Pharma

A Big, Fatty Opportunity for Big Pharma The next multibillion-dollar therapeutic area for drug companies may be fatty liver disease, but there are a few practical hurdles to overcome first.  The next big opportunity for pharmaceutical companies is in a disease many people don’t know about. Investors and industry observers should expect to hear…

Read More

Liver Disease Risks – NAFLD

Non-Alcoholic Fatty Liver Disease WHILE much is known about the damaging effects of alcohol on the liver, and indeed the body as a whole, perhaps less is known about the condition referred to as Non-Alcoholic Fatty Liver Disease (NAFLD). Previously thought to be entirely harmless, NAFLD is estimated to affect up to one in five…

Read More